Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Section 5 of 6

Economic information and modeling report

11 evidence topics · 10 sources

Modeling overview

Summary

No cost-effectiveness or budget impact model of claseprubart has been published. Published analyses in CIDP evaluate efgartigimod alfa and immunoglobulin. CDA-AMC estimated an incremental cost-effectiveness ratio for efgartigimod alfa injection of $1,872,111 per QALY gained compared with immunoglobulin, and recommended reimbursement with conditions, including that its total cost not exceed that of immunoglobulin after the first 6 months. The second NICE draft guidance, open for consultation from 03 November 2026 to 23 November 2026, states that efgartigimod should not be used to treat progressive or relapsing active CIDP in adults after corticosteroids or immunoglobulins, with publication expected on 24 February 2027. A model from a US integrated delivery network perspective projected a total budget impact of $45,996,708, a 35.5% increase, from 10% uptake of efgartigimod alfa in year 1 among an expected 708 immunoglobulin-treated individuals with CIDP in a hypothetical 25-million-member health plan. A Markov model of 5 years of treatment estimated an incremental cost per QALY gained of $687,287 for intravenous immunoglobulin compared with corticosteroids. The company assumes an immunoglobulin price per patient of approximately $150,000 per year and an average biologic net price per patient of approximately $700,000 per year in the US CIDP market.

CDA-AMC reimbursement recommendation for efgartigimod alfa injection in CIDP: cost-effectiveness and budget impact

“Final recommendation: Reimburse with conditions” (opens the source at this quote in a new tab)

“Treatment costs: At the submitted price of $19,750.00 per 5 mL single-dose prefilled syringe, the annual cost of efgartigimod alfa injection is expected to be $1,030,527 per patient, based on the Health Canada–recommended dosage.” (opens the source at this quote in a new tab)

“Cost of efgartigimod alfa injection versus relevant comparators: Efgartigimod alfa injection is predicted to be associated with higher costs to the health care system than Ig (incremental costs = $6,405,231 per patient), primarily driven by increased costs associated with drug acquisition.” (opens the source at this quote in a new tab)

“Key findings of the economic evaluation: Based on the submitted evidence using the sponsor’s cost-utility analysis, the CDA-AMC base-case analysis estimated that the incremental cost-effectiveness ratio (ICER) for efgartigimod alfa injection in CIDP was $1,872,111 per QALY gained when compared with Ig.” (opens the source at this quote in a new tab)

“The cost-effectiveness of efgartigimod alfa injection versus off-label comparators such as corticosteroids, PLEX, immunosuppressives, and rituximab remains unknown.” (opens the source at this quote in a new tab)

“Anticipated budget impact: CDA-AMC estimated that by year 3 of reimbursement, 2,525 patients would be eligible for treatment with efgartigimod alfa injection, of whom 379 would be expected to receive efgartigimod alfa injection.” (opens the source at this quote in a new tab)

“The estimated incremental budget impact of reimbursing efgartigimod alfa injection is predicted to be approximately $691 million over the first 3 years, with an expected expenditure of $692 million on efgartigimod alfa injection.” (opens the source at this quote in a new tab)

“After the first 6 months of treatment, Vyvgart SC will only be covered if there is clinical stability in symptoms using at least 1 approved assessment tool and if the total cost of Vyvgart SC does not exceed the total cost of Ig treatment.” (opens the source at this quote in a new tab)

CDA-AMC economic review of the sponsor's cost-utility model for efgartigimod alfa injection in CIDP

NICE draft guidance on efgartigimod for CIDP (ID6409): recommendation and model structure

“Efgartigimod should not be used to treat progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) in adults after corticosteroids or immunoglobulins.” (opens the source at this quote in a new tab)

“The list price of efgartigimod is £15,307.47 for a pre-filled 5-ml syringe containing 1,000 mg of efgartigimod (200 mg per ml; excluding VAT, sourced from company submission).” (opens the source at this quote in a new tab)

“The company presented a Markov model with time-varying transition probabilities. The health states were defined based on both disease severity and whether the disease was active or in remission.” (opens the source at this quote in a new tab)

“The company’s model had a lifetime horizon (45 years) and a 6-monthly cycle.” (opens the source at this quote in a new tab)

“The committee was aware that immunoglobulins are not recommended by NICE and are likely to be highly cost-ineffective treatments. It noted that the company’s model estimated a very high cost per person (over £1.5 million) over the model time horizon.” (opens the source at this quote in a new tab)

“The exact cost-effectiveness estimates cannot be reported here because of confidential discounts. The company’s base-case ICER using some of the committee’s preferred assumptions was substantially above the range normally considered to be a cost-effective use of NHS resources.” (opens the source at this quote in a new tab)

Cost-utility of intravenous immunoglobulin compared with prednisolone in a European crossover trial

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.